Oncology News Central Peer-Spectives

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Richard Finn, MD, Professor of Medicine at the Geffen School of Medicine, UCLA, discuss hepatocellular carcinoma (HCC) clinical highlights from ASCO GI 2019

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Tanios Bekaii-Saab, MD, Professor, Mayo Clinic College of Medicine and Science, discuss biliary tract and GE junction cancer clinical highlights from ASCO GI 2019

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Frederick Locke, MD, Program Co-Leader, Immunology, Moffitt Cancer Center discuss CAR-T clinical highlights from ASH 2018

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Sagar Lonial, MD, Professor and Chair, Hematology & Medical Oncology, Chief Medical Officer, Winship Cancer Institute of Emory University, discuss ALCYONE, GRIFFIN, and maintenance therapy (TOURMALINE-MM3), and other multiple myeloma clinical studies presented at the American Society of Hematology 2018 meeting

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Debu Tripathy, MD, Professor and Chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, MD Anderson, discuss IMpassion130, SOLAR-1 and other breast cancer clinical studies presented at the meeting

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Barbara Burtness, MD, Professor of Medicine (Medical Oncology) at the Yale University School of Medicine, discuss Keynote-048 and other H&N clinical studies presented at the meeting

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Bradley Monk, MD, FACOG, FACS, Professor and Director of the Division of Gynecologic Oncology at Creighton University School of Medicine, discuss BRCA1+ ovarian patients, PARP inhibitors and the results of the SOLO-1 clinical trial

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center speaks with Melissa Johnson, MD, Associate Director, Lung Cancer Research, Sarah Cannon Research Institute about targeted therapy, prevention, I-O in NSCLC, and I-O in SCLC.

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center speaks with Paul Bunn, MD, Distinguished Professor, Division of Medical Oncology, University of Colorado about prevention, I-O in NSCLC, and I-O in SCLC.